Patents by Inventor Michael J. Robarge
Michael J. Robarge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9096520Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).Type: GrantFiled: March 21, 2014Date of Patent: August 4, 2015Assignee: ABT Holding CompanyInventors: Youssef L. Bennani, Bayard Huck, Michael J. Robarge
-
Publication number: 20140206739Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).Type: ApplicationFiled: March 21, 2014Publication date: July 24, 2014Applicant: ABT Holding CompanyInventors: Youssef L. Bennani, Bayard Huck, Michael J. Robarge
-
Publication number: 20140206672Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are thiophenyl and pyrrolyl azepine compounds. These compounds are serotonin receptor (5-HT2c) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT2c) is desired (e.g. addiction, anxiety, depression, obesity, and others).Type: ApplicationFiled: March 19, 2014Publication date: July 24, 2014Applicant: ABT Holding CompanyInventors: L. Nathan Tumey, David C. Bom, Youssef L. Bennani, Michael J. Robarge
-
Patent number: 8716324Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).Type: GrantFiled: June 18, 2012Date of Patent: May 6, 2014Assignee: Athersys, Inc.Inventors: Youssef L. Bennani, Bayard Huck, Michael J. Robarge
-
Patent number: 8716276Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are thiophenyl and pyrrolyl azepine compounds. These compounds are serotonin receptor (5-HT2c) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT2c) is desired (e.g. addiction, anxiety, depression, obesity, and others).Type: GrantFiled: January 12, 2011Date of Patent: May 6, 2014Assignee: Athersys, Inc.Inventors: L. Nathan Tumey, David C. Bom, Youssef L. Bennani, Michael J. Robarge
-
Publication number: 20120252859Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).Type: ApplicationFiled: June 18, 2012Publication date: October 4, 2012Applicant: ATHERSYS, INC.Inventors: Youssef L. Bennani, Bayard Huck, Michael J. Robarge
-
Patent number: 8232311Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).Type: GrantFiled: March 25, 2011Date of Patent: July 31, 2012Assignee: Athersys, Inc.Inventors: Youssef L. Bennani, Bayard Huck, Michael J. Robarge
-
Patent number: 8012997Abstract: The invention relates to isoindole-imide compounds and pharmaceutically acceptable salts, hydrates, solvates, clathrates, enantiomers, diastereomers, racemates, or mixtures of stereoisomers thereof, pharmaceutical compositions comprising these isoindole-imide compounds, and methods for reducing the level of cytokines and their precursors in mammals. In particular, the invention pertains to isoindole-imide compounds that are potent inhibitors of the production of TNF-? in mammals. The isoindole-imides described herein are useful for treating or preventing diseases or disorders in mammals, for example, cancers, such as solid tumors and blood-born tumors; heart disease, such as congestive heart failure; osteoporosis; and genetic, inflammatory; allergic; and autoimmune diseases.Type: GrantFiled: July 23, 2009Date of Patent: September 6, 2011Assignee: Celgene CorporationInventors: Michael J. Robarge, Roger Shen-Chu Chen, George W. Muller, Hon-Wah Man
-
Patent number: 7981919Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).Type: GrantFiled: August 5, 2008Date of Patent: July 19, 2011Assignee: Athersys, Inc.Inventors: Youssef L. Bennani, David C. Bom, Michael J. Robarge
-
Publication number: 20110172283Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).Type: ApplicationFiled: March 25, 2011Publication date: July 14, 2011Inventors: Youssef L. Bennani, Bayard Huck, Michael J. Robarge
-
Publication number: 20110112072Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are thiophenyl and pyrrolyl azepine compounds. These compounds are serotonin receptor (5-HT2c) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT2c) is desired (e.g. addiction, anxiety, depression, obesity, and others).Type: ApplicationFiled: January 12, 2011Publication date: May 12, 2011Inventors: L. Nathan Tumey, David C. Bom, Youssef L. Bennani, Michael J. Robarge
-
Patent number: 7935830Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).Type: GrantFiled: June 4, 2009Date of Patent: May 3, 2011Assignee: Athersys, Inc.Inventors: Youssef L. Bennani, Bayard Huck, Michael J. Robarge
-
Patent number: 7893051Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are thiophenyl and pyrrolyl azepine compounds. These compounds are serotonin receptor (5-HT2c) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT2c) is desired (e.g. addiction, anxiety, depression, obesity, and others).Type: GrantFiled: January 17, 2007Date of Patent: February 22, 2011Assignee: Athersys, Inc.Inventors: L. Nathan Tumey, David C. Bom, Youssef L. Bennani, Michael J. Robarge
-
Publication number: 20100190772Abstract: The present invention generally relates to compounds and pharmaceutical compositions containing the compounds. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).Type: ApplicationFiled: April 1, 2010Publication date: July 29, 2010Inventors: Youssef L. Bennani, Michael J. Robarge, David C. Bom, Norbert Varga, Lawrence N. Tumey
-
Patent number: 7718647Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).Type: GrantFiled: June 29, 2005Date of Patent: May 18, 2010Assignee: Athersys, Inc.Inventors: Youssef L. Bennani, Michael J. Robarge, David C. Bom, Norbert Varga, Lawrence N. Tumey
-
Publication number: 20090286986Abstract: The invention relates to isoindole-imide compounds and pharmaceutically acceptable salts, hydrates, solvates, clathrates, enantiomers, diastereomers, racemates, or mixtures of stereoisomers thereof, pharmaceutical compositions comprising these isoindole-imide compounds, and methods for reducing the level of cytokines and their precursors in mammals. In particular, the invention pertains to isoindole-imide compounds that are potent inhibitors of the production of TNF-? in mammals. The isoindole-imides described herein are useful for treating or preventing diseases or disorders in mammals, for example, cancers, such as solid tumors and blood-born tumors; heart disease, such as congestive heart failure; osteoporosis; and genetic, inflammatory; allergic; and autoimmune diseases.Type: ApplicationFiled: July 23, 2009Publication date: November 19, 2009Inventors: Michael J. Robarge, Roger Shen-Chu Chen, George W. Muller, Hon-Wah Man
-
Publication number: 20090239925Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).Type: ApplicationFiled: June 4, 2009Publication date: September 24, 2009Inventors: Youssef L. Bennani, Bayard Huck, Michael J. Robarge
-
Patent number: 7576104Abstract: The invention relates to isoindole-imide compounds and pharmaceutically acceptable salts, hydrates, solvates, clathrates, enantiomers, diastereomers, racemates, or mixtures of stereoisomers thereof, pharmaceutical compositions comprising these isoindole-imide compounds, and methods for reducing the level of cytokines and their precursors in mammals. In particular, the invention pertains to isoindole-imide compounds that are potent inhibitors of the production of TNF-? in mammals. The isoindole-imides described herein are useful for treating or preventing diseases or disorders in mammals, for example, cancers, such as solid tumors and blood-born tumors; heart disease, such as congestive heart failure; osteoporosis; and genetic, inflammatory; allergic; and autoimmune diseases.Type: GrantFiled: September 21, 2005Date of Patent: August 18, 2009Assignee: Celgene CorporationInventors: Michael J. Robarge, Roger Shen-Chu Chen, George W. Muller, Hon-Wah Man
-
Publication number: 20090069365Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).Type: ApplicationFiled: August 5, 2008Publication date: March 12, 2009Inventors: Youssef L. Bennani, David C. Bom, Michael J. Robarge
-
Patent number: 7470723Abstract: The present invention relates to Diphenylethylene Compounds and compositions comprising a Diphenylethylene Compound. The present invention also relates to methods for preventing or treating various diseases and disorders by administering to a subject in need thereof one or more Diphenylethylene Compounds. In particular, the invention relates to methods for preventing or treating cancer or an inflammatory disorder by administering to a subject in need thereof one or more Diphenylethylene Compounds. The present invention further relates to articles of manufacture and kits comprising one or more Diphenylethylene Compounds.Type: GrantFiled: September 3, 2004Date of Patent: December 30, 2008Assignee: Celgene CorporationInventors: George W. Muller, Faribourz Payvandi, Ling H. Zhang, Michael J. Robarge, Roger Chen, Hon-Wah Man, Alexander L. Ruchelman